Clinical Low Risk Prostate Cancer: What Can We Tell The Patient At Diagnosis?

Main Category: Prostate / Prostate Cancer
Also Included In: Urology / Nephrology
Article Date: 06 Jun 2008 - 7:00 PDT

email to a friend   printer friendly   opinions  

ORLANDO, FL (UroToday.com) - Simon Kim and colleagues examined outcomes for low risk prostate cancer patients (PSA <10, Gleason 6, clinical stage T1C) who undergo radical retropubic prostatectomy (n=846).

The outcomes were impressive. 10 years after radical prostatectomy, PSA-free survival and prostate cancer specific survival were 94.5% and 99.8%, respectively. Only 3 patients (0.35%) died of prostate cancer in this group. Should we pat ourselves on the back?

Let's compare this group to a similar cohort with 10-year follow-up on active surveillance first.

Presented by Simon P Kim, MD, Jessica Labo, MD, Stephanie Daignault, MD, David P Wood, MD, at the Annual Meeting of the American Urological Association (AUA) - May 17 - 22, 2008. Orange County Convention Center - Orlando, Florida, USA.

Reported by UroToday.com Contributing Editor Alexander Kutikov, MD

UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.

To access the latest urology news releases from UroToday, go to: www.urotoday.com

Copyright © 2008 - UroToday

• Additional
• References
• Citations